[go: up one dir, main page]

MX2024015351A - Composicion farmaceutica para tratar y resistir a la coagulacion sanguinea y uso de la misma - Google Patents

Composicion farmaceutica para tratar y resistir a la coagulacion sanguinea y uso de la misma

Info

Publication number
MX2024015351A
MX2024015351A MX2024015351A MX2024015351A MX2024015351A MX 2024015351 A MX2024015351 A MX 2024015351A MX 2024015351 A MX2024015351 A MX 2024015351A MX 2024015351 A MX2024015351 A MX 2024015351A MX 2024015351 A MX2024015351 A MX 2024015351A
Authority
MX
Mexico
Prior art keywords
sub
treating
pharmaceutical composition
blood coagulation
resisting blood
Prior art date
Application number
MX2024015351A
Other languages
English (en)
Inventor
Hai Zhang
Yu Nie
Xia Mou
Yongwen Su
Zeqin Yi
Original Assignee
Chengdu Shibeikang Biomedical Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Shibeikang Biomedical Tech Co Ltd filed Critical Chengdu Shibeikang Biomedical Tech Co Ltd
Publication of MX2024015351A publication Critical patent/MX2024015351A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición para tratar y resistir la coagulación sanguínea y a su uso, y particularmente se refiere a una composición farmacéutica que contiene (7aS, 2'S)-2-oxo-clopidogrel y a su uso. La presente invención proporciona una especificación medicinal de una preparación sólida que, después de la administración oral antes/después de las comidas para su uso en adultos sanos, puede ser similar a los comprimidos de bisulfato de clopidogrel que son 12,5 veces más grandes en especificación en términos de Cmáx, ABC(0-t) y ABC(0-8) de un compuesto A producido metabólicamente y un metabolito activo H4, asegurando así la eficacia y seguridad del uso de la medicación.
MX2024015351A 2022-06-17 2024-12-10 Composicion farmaceutica para tratar y resistir a la coagulacion sanguinea y uso de la misma MX2024015351A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210688248.6A CN115518066A (zh) 2022-06-17 2022-06-17 一种用于治疗抗凝血的药物组合物及应用
PCT/CN2023/100638 WO2023241688A1 (zh) 2022-06-17 2023-06-16 一种用于治疗抗凝血的药物组合物及应用

Publications (1)

Publication Number Publication Date
MX2024015351A true MX2024015351A (es) 2025-02-10

Family

ID=84696535

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024015351A MX2024015351A (es) 2022-06-17 2024-12-10 Composicion farmaceutica para tratar y resistir a la coagulacion sanguinea y uso de la misma

Country Status (11)

Country Link
US (1) US20260007641A1 (es)
EP (1) EP4541353A1 (es)
JP (1) JP2025519762A (es)
KR (1) KR20250016304A (es)
CN (1) CN115518066A (es)
AU (1) AU2023290344A1 (es)
CA (1) CA3258707A1 (es)
CO (1) CO2024017149A2 (es)
MX (1) MX2024015351A (es)
WO (1) WO2023241688A1 (es)
ZA (1) ZA202409443B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115518066A (zh) * 2022-06-17 2022-12-27 成都施贝康生物医药科技有限公司 一种用于治疗抗凝血的药物组合物及应用
CN116262116A (zh) * 2022-12-02 2023-06-16 成都施贝康生物医药科技有限公司 一种含氧化氯吡格雷的固体制剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006336417A1 (en) * 2005-05-10 2007-08-02 Elan Pharma International, Limited Nanoparticulate clopidogrel formulations
CN101653420A (zh) * 2009-09-08 2010-02-24 中国科学院化学研究所 超声控释靶向药物制剂及其制备方法
AU2011294757B2 (en) * 2010-08-26 2015-11-05 Ipca Laboratories Limited Methods for the treatment or prophylaxis of thrombosis or embolism
SG195257A1 (en) * 2011-06-27 2013-12-30 Ipca Lab Ltd Anti-thrombotic compounds
CN112076190B (zh) * 2019-06-14 2023-04-07 成都施贝康生物医药科技有限公司 一种含有难溶性噻吩并吡啶组合物的固体制剂及制备方法
WO2021070200A2 (en) * 2019-10-08 2021-04-15 Ipca Laboratories Limited Stable compositions of (7as,2's)-2-oxoclopidogrel and its pharmaceutical salts
CN111150731A (zh) * 2020-01-19 2020-05-15 成都施贝康生物医药科技有限公司 含氧吡格雷光学异构体或其盐的组合物及应用
CN111166745A (zh) * 2020-01-19 2020-05-19 成都施贝康生物医药科技有限公司 含消旋氧吡格雷或其盐的组合物及应用
CN115518066A (zh) * 2022-06-17 2022-12-27 成都施贝康生物医药科技有限公司 一种用于治疗抗凝血的药物组合物及应用

Also Published As

Publication number Publication date
CO2024017149A2 (es) 2024-12-19
CA3258707A1 (en) 2025-06-12
EP4541353A1 (en) 2025-04-23
KR20250016304A (ko) 2025-02-03
JP2025519762A (ja) 2025-06-26
US20260007641A1 (en) 2026-01-08
ZA202409443B (en) 2025-08-27
CN115518066A (zh) 2022-12-27
AU2023290344A1 (en) 2025-01-02
WO2023241688A1 (zh) 2023-12-21

Similar Documents

Publication Publication Date Title
MX2024015351A (es) Composicion farmaceutica para tratar y resistir a la coagulacion sanguinea y uso de la misma
US12220392B2 (en) Combination composition
RU2010105122A (ru) Композиции для ухода за полостью рта, продукты и способы применения
Ma et al. A comprehensive review of natural products to fight liver fibrosis: Alkaloids, terpenoids, glycosides, coumarins and other compounds
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
RU2010109359A (ru) Азитромицин для лечения кожных заболеваний
RU2007101686A (ru) Комбинированная композиция
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
BR0109747A (pt) Uso de 5-(2-pirazinil)-4-metil-1-2-ditiol-3-tiona (oltipraz) como um medicamento, composição farmacêutica para a prevenção e tratamento da progressão da fibrose hepática, uso de 5-(2-pirazinil)-4-metil-1, 2-ditiol-3-tiona e método para a prevenção e tratamento da progressão da fibrose e da cirrose hepática
JPH05246845A (ja) イブプロフェン含有解熱鎮痛剤
US3019165A (en) Sunburn preventive and burn remedy
KR102671524B1 (ko) 구역 반사의 치료를 위한 조성물 및 요법
DE60331920D1 (de) Orale pharmazeutische zusammensetzung für weichkapseln mit vinorelbin und behandlungsverfahren
AR034036A1 (es) Inhibidor de aromatasa en una dosis unica para tratar la infertilidad
US4042698A (en) Treatment of myasthenia gravis and oral medication therefor
HUP9900521A2 (hu) Eljárás nagyon kis dózisú hatóanyagok szilárd dózisformáinak előállítására
AR062894A1 (es) Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths)
US20190381034A1 (en) Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases
JP2019001830A (ja) 医薬
US3574834A (en) Medicinal soporific composition
JPH0848639A (ja) 改善された血圧上昇薬
CN111494372A (zh) 一种牙周疾病治疗方法
Kamimura et al. Drug therapy for depression in Japan
Litt A chronicle of racism
UA124257U (uk) Лікарський засіб у вигляді м'яких капсул для орального застосування, який містить симетикон